Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:BVXVNASDAQ:CYTROTCMKTS:ENZNNYSE:IKT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$0.66-24.9%$11.13$0.61▼$24.20$820K1.4119,299 shs416,900 shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsENZNEnzon Pharmaceuticals$0.08+14.7%$0.08$0.06▼$0.23N/A0.3319,282 shs125 shsIKTInhibikase Therapeutics$1.58+15.3%$2.19$0.79▼$4.35$10.24M1.19127,727 shs79,090 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%-94.54%-96.11%-92.97%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%-28.80%CYTRLadRx0.00%0.00%0.00%0.00%0.00%ENZNEnzon Pharmaceuticals+7.79%+20.37%+11.43%-11.94%-62.63%IKTInhibikase Therapeutics+15.33%-26.85%-29.15%-46.62%-54.60%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYTRLadRxN/AN/AN/AN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIKTInhibikase Therapeutics1.4407 of 5 stars3.50.00.00.00.01.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/ACYTRLadRxN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AIKTInhibikase Therapeutics3.00Buy$27.001,608.86% UpsideCurrent Analyst RatingsLatest ACOR, BVXV, ENZN, CYTR, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.01$33.05 per share0.02($127.17) per share-0.01BVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/ACYTRLadRxN/AN/AN/AN/AN/AN/AENZNEnzon Pharmaceuticals$30KN/AN/AN/AN/AN/AIKTInhibikase Therapeutics$260K39.38N/AN/A$1.78 per share0.89Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/A∞N/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)BVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/ACYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/AENZNEnzon Pharmaceuticals$1.37M$0.017.80∞N/AN/A46.47%2.92%N/AIKTInhibikase Therapeutics-$19.03M-$3.56N/AN/AN/A-5,886.15%-107.54%-91.82%5/20/2024 (Estimated)Latest ACOR, BVXV, ENZN, CYTR, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023IKTInhibikase Therapeutics-$0.78-$0.63+$0.15-$0.63N/AN/A 3/20/2024Q4 2023ENZNEnzon PharmaceuticalsN/A$0.01+$0.01$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/ACYTRLadRxN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26BVXVBiondVax PharmaceuticalsN/A4.124.12CYTRLadRxN/AN/AN/AENZNEnzon PharmaceuticalsN/A27.6227.62IKTInhibikase TherapeuticsN/A4.134.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%BVXVBiondVax Pharmaceuticals11.83%CYTRLadRxN/AENZNEnzon PharmaceuticalsN/AIKTInhibikase Therapeutics3.81%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%BVXVBiondVax Pharmaceuticals6.03%CYTRLadRxN/AENZNEnzon Pharmaceuticals0.27%IKTInhibikase Therapeutics20.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableCYTRLadRxN/A45.04 millionN/ANot OptionableENZNEnzon PharmaceuticalsN/AN/AN/ANot OptionableIKTInhibikase Therapeutics86.48 million5.16 millionNot OptionableACOR, BVXV, ENZN, CYTR, and IKT HeadlinesSourceHeadlineLexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare moversmsn.com - April 22 at 11:13 AMInhibikase Therapeutics progresses in Parkinson's disease trialsinvesting.com - April 20 at 3:26 PMInhibikase sees “opportunity” in cardiopulmonary disease for IkT-001Propharmaceutical-technology.com - April 19 at 1:44 PMInhibikase Therapeutics (NYSE:IKT) Stock Price Down 1.4%americanbankingnews.com - April 19 at 2:40 AMInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programsglobenewswire.com - April 18 at 4:30 PMInhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick Factsmarkets.businessinsider.com - April 3 at 10:50 AMInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertensionglobenewswire.com - April 3 at 8:05 AMBuy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progressmarkets.businessinsider.com - April 3 at 1:15 AMInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 3:03 PMInhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectationsfinance.yahoo.com - April 2 at 3:03 PMQ4 2023 Inhibikase Therapeutics Inc Earnings Callfinance.yahoo.com - March 29 at 12:18 AMInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activityglobenewswire.com - March 27 at 4:15 PMInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disordersfinance.yahoo.com - March 7 at 9:46 AMInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disordersglobenewswire.com - March 7 at 8:30 AMInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disordersglobenewswire.com - March 7 at 8:30 AMBuy Rating Backed by Promising Developments and Regulatory Confidence in Inhibikase’s Pipelinemarkets.businessinsider.com - March 6 at 5:56 PMHC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - March 5 at 12:20 PMInhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Proglobenewswire.com - February 28 at 4:05 PMInhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial Standingmarkets.businessinsider.com - February 21 at 11:55 PMHere's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Nowfinance.yahoo.com - February 15 at 1:54 PMHere's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Nowzacks.com - February 15 at 10:56 AMInhibikase Therapeutics Inc (IKT)investing.com - February 10 at 1:10 PMInhibikase Discusses FDA Pathway for New Cancer Drugmsn.com - February 8 at 9:09 AMTenax Therapeutics, Equillium among healthcare moversmsn.com - February 7 at 1:07 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.BiondVax PharmaceuticalsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.LadRxNASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.Enzon PharmaceuticalsOTCMKTS:ENZNEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Inhibikase TherapeuticsNYSE:IKTInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.